0QMX Stock Overview
Develops and markets personal telemedicine solutions in Israel, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SHL Telemedicine Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 4.13 |
| 52 Week High | CHF 10.23 |
| 52 Week Low | CHF 4.13 |
| Beta | 0.38 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -53.33% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -49.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QMX | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.6% | 0.03% |
| 1Y | -53.3% | -12.9% | 7.4% |
Return vs Industry: 0QMX underperformed the UK Healthcare industry which returned -12.9% over the past year.
Return vs Market: 0QMX underperformed the UK Market which returned 7.4% over the past year.
Price Volatility
| 0QMX volatility | |
|---|---|
| 0QMX Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QMX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0QMX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 583 | David Arnon | www.shl-telemedicine.com |
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen’C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio’B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use.
SHL Telemedicine Ltd. Fundamentals Summary
| 0QMX fundamental statistics | |
|---|---|
| Market cap | CHF 49.67m |
| Earnings (TTM) | -CHF 7.48m |
| Revenue (TTM) | CHF 47.30m |
1.0x
P/S Ratio-6.6x
P/E RatioIs 0QMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QMX income statement (TTM) | |
|---|---|
| Revenue | US$55.94m |
| Cost of Revenue | US$30.36m |
| Gross Profit | US$25.58m |
| Other Expenses | US$34.42m |
| Earnings | -US$8.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 45.73% |
| Net Profit Margin | -15.80% |
| Debt/Equity Ratio | 15.9% |
How did 0QMX perform over the long term?
See historical performance and comparison